158 related articles for article (PubMed ID: 9816085)
1. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma.
Ockert D; Schirrmacher V; Beck N; Stoelben E; Ahlert T; Flechtenmacher J; Hagmüller E; Buchcik R; Nagel M; Saeger HD
Clin Cancer Res; 1996 Jan; 2(1):21-8. PubMed ID: 9816085
[TBL] [Abstract][Full Text] [Related]
2. [Adjuvant therapy of liver metastases: active specific immunotherapy].
Hagmüller E; Beck N; Ockert D; Schirrmacher V
Zentralbl Chir; 1995; 120(10):780-5. PubMed ID: 7502592
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study.
Galligioni E; Quaia M; Merlo A; Carbone A; Spada A; Favaro D; Santarosa M; Sacco C; Talamini R
Cancer; 1996 Jun; 77(12):2560-6. PubMed ID: 8640706
[TBL] [Abstract][Full Text] [Related]
4. Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2.
Janke M; Peeters B; Zhao H; de Leeuw O; Moorman R; Arnold A; Ziouta Y; Fournier P; Schirrmacher V
Int J Oncol; 2008 Oct; 33(4):823-32. PubMed ID: 18813797
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits.
Uyl-de Groot CA; Vermorken JB; Hanna MG; Verboom P; Groot MT; Bonsel GJ; Meijer CJ; Pinedo HM
Vaccine; 2005 Mar; 23(17-18):2379-87. PubMed ID: 15755632
[TBL] [Abstract][Full Text] [Related]
6. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus.
Schirrmacher V; Haas C; Bonifer R; Ahlert T; Gerhards R; Ertel C
Gene Ther; 1999 Jan; 6(1):63-73. PubMed ID: 10341877
[TBL] [Abstract][Full Text] [Related]
7. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials.
Mosolits S; Nilsson B; Mellstedt H
Expert Rev Vaccines; 2005 Jun; 4(3):329-50. PubMed ID: 16026248
[TBL] [Abstract][Full Text] [Related]
8. Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccine.
Lehner B; Schlag P; Liebrich W; Schirrmacher V
Cancer Immunol Immunother; 1990; 32(3):173-8. PubMed ID: 2289211
[TBL] [Abstract][Full Text] [Related]
9. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial.
Schlag P; Manasterski M; Gerneth T; Hohenberger P; Dueck M; Herfarth C; Liebrich W; Schirrmacher V
Cancer Immunol Immunother; 1992; 35(5):325-30. PubMed ID: 1394336
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy of renal cell carcinoma with active-specific-immunotherapy (ASI) using autologous tumor vaccine.
Repmann R; Wagner S; Richter A
Anticancer Res; 1997; 17(4B):2879-82. PubMed ID: 9329553
[TBL] [Abstract][Full Text] [Related]
11. Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guérin vaccine.
Hoover HC; Surdyke M; Dangel RB; Peters LC; Hanna MG
Cancer Res; 1984 Apr; 44(4):1671-6. PubMed ID: 6704973
[TBL] [Abstract][Full Text] [Related]
12. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells.
Karcher J; Dyckhoff G; Beckhove P; Reisser C; Brysch M; Ziouta Y; Helmke BH; Weidauer H; Schirrmacher V; Herold-Mende C
Cancer Res; 2004 Nov; 64(21):8057-61. PubMed ID: 15520216
[TBL] [Abstract][Full Text] [Related]
13. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
14. Immunization with virus-modified tumor cells.
Schirrmacher V; Ahlert T; Pröbstle T; Steiner HH; Herold-Mende C; Gerhards R; Hagmüller E; Steiner HH
Semin Oncol; 1998 Dec; 25(6):677-96. PubMed ID: 9865682
[TBL] [Abstract][Full Text] [Related]
15. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract.
Liang W; Wang H; Sun TM; Yao WQ; Chen LL; Jin Y; Li CL; Meng FJ
World J Gastroenterol; 2003 Mar; 9(3):495-8. PubMed ID: 12632504
[TBL] [Abstract][Full Text] [Related]
16. Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H).
Csatary LK; Moss RW; Beuth J; Töröcsik B; Szeberenyi J; Bakacs T
Anticancer Res; 1999; 19(1B):635-8. PubMed ID: 10216468
[TBL] [Abstract][Full Text] [Related]
17. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit.
Steiner HH; Bonsanto MM; Beckhove P; Brysch M; Geletneky K; Ahmadi R; Schuele-Freyer R; Kremer P; Ranaie G; Matejic D; Bauer H; Kiessling M; Kunze S; Schirrmacher V; Herold-Mende C
J Clin Oncol; 2004 Nov; 22(21):4272-81. PubMed ID: 15452186
[TBL] [Abstract][Full Text] [Related]
18. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
Posner MC; Niedzwiecki D; Venook AP; Hollis DR; Kindler HL; Martin EW; Schilsky RL; Goldberg RM; Mayer RJ
Ann Surg Oncol; 2008 Jan; 15(1):158-64. PubMed ID: 18008108
[TBL] [Abstract][Full Text] [Related]
19. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial.
Schulze T; Kemmner W; Weitz J; Wernecke KD; Schirrmacher V; Schlag PM
Cancer Immunol Immunother; 2009 Jan; 58(1):61-9. PubMed ID: 18488223
[TBL] [Abstract][Full Text] [Related]
20. Active specific immunotherapy with an autologous tumor cell vaccine in patients with resected non-small cell lung cancer.
Schulof RS; Mai D; Nelson MA; Paxton HM; Cox JW; Turner ML; Mills M; Hix WR; Nochomovitz LE; Peters LC
Mol Biother; 1988; 1(1):30-6. PubMed ID: 2855788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
